Insights Into Chronic Lymphocytic Leukemia (CLL) – Northwest
Perspectives of community physicians from the northwest region of the United States on the management of newly diagnosed and relapsed/refractory CLL
Northwest – November 9, 2020
Faculty Chair
John M. Pagel, MD, PhD
Swedish Cancer Institute, Seattle, WA, US
REPORT TOPICS INCLUDE
- Insights from a moderated roundtable discussion focusing on treatment of CLL
- Insights on the following CLL therapies: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, BR
- Data collected via audience response system questioning and in-depth moderated discussion
GEOGRAPHIC REPRESENTATION
- The group of advisors comprised 10 community oncologists from the northwest region of the United States
